-
Accuracy of Information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO Guidelines J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-23 Martina Sciberras, Yvette Farrugia, Hannah Gordon, Federica Furfaro, Mariangela Allocca, Joana Torres, Naila Arebi, Gionata Fiorino, Marietta Iacucci, Bram Verstockt, Fernando Magro, Kostas Katsanos, Josef Busuttil, Katya De Giovanni, Valerie Anne Fenech, Stefania Chetcuti Zammit, Pierre Ellul
Introduction As acceptance of AI platforms increases, more patients will consider these tools as sources of information. The ChatGPT architecture utilizes a neural network to process natural language, thus generating responses based on the context of input text. The accuracy and completeness of ChatGPT3.5 in the context of Inflammatory Bowel Disease remains unclear. Methods In this prospective study
-
Spondyloarthritis in first-degree relatives and spouses of patients with inflammatory bowel disease: A nationwide population-based cohort study from Sweden J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-22 Sarita Shrestha, Judith S Brand, Mehdi Osooli, Carl Eriksson, Ida Schoultz, Johan Askling, Tine Jess, Scott Montgomery, Ola Olén, Jonas Halfvarson
Background and Aims Register-based research suggests a shared pathophysiology between inflammatory bowel disease [IBD] and spondyloarthritis [SpA], but the role of familial [genetic and environmental] factors in this shared susceptibility is largely unknown. We compared the risk of SpA in first-degree relatives [FDRs] and spouses of IBD patients with FDRs and spouses of matched population-based reference
-
Histological Outcomes And Jak-Stat Signalling In Ulcerative Colitis Patients Treated With Tofacitinib J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-20 Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, Jitteke de Jong, Leonie C S de Vries, Wouter J de Jonge, Krisztina B Gecse, Mark Löwenberg, John C Woolcott, Aart Mookhoek, Geert R D’Haens
Background and aims Histological outcomes and JAK-STAT signaling were assessed in a prospective ulcerative colitis (UC) patient cohort after 8 weeks treatment with tofacitinib, an oral Janus kinase (JAK) inhibitor. Methods Forty UC patients received tofacitinib 10 mg twice daily for 8 weeks. Treatment response was defined as histo-endoscopic mucosal improvement (HEMI). Histological remission was defined
-
Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-18 Danny Con, Patrick Hilley, Simone Chin, Crispin Corte, Bilal Hafeez, Adam Testro, Peter De Cruz, Matthew Choy, Ashish Srinivasan
Background The management of inflammatory bowel disease (IBD) patients with concurrent liver transplantation is challenging, and data regarding the safety and efficacy of Janus kinase (JAK) inhibitors with anti-rejection medications are required. We report the experience of all liver transplant recipients receiving tofacitinib and/or upadacitinib for IBD across three states in Australia. Methods All
-
Does combined medical and surgical treatment improve perianal fistula outcomes in patients with Crohn’s disease? A systematic review and meta-analysis J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-15 Moses Fung, Yasamin Farbod, Husain Kankouni, Siddharth Singh, Jeffrey D McCurdy
BACKGROUND The optimal treatment of perianal fistulizing Crohn’s disease (PFCD) is unknown. We performed a systematic review with meta-analysis to compare combined surgical intervention and anti-TNF therapy (combined therapy) vs. either therapy alone. METHODS MEDLINE, EMBASE, and Cochrane databases were searched systematically through December 2023. Surgical intervention was defined as an exam under
-
Intestinal adipocytes transdifferentiate into myofibroblast-like cells and contribute to fibrosis in Crohn's disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-11 Zhijun Geng, Jing Li, Lugen Zuo, Xiaofeng Zhang, Lian Wang, Yongsheng Xia, Jingjing Yang, Lixia Yin, Xue Song, Yueyue Wang, Damin Chai, Min Deng, Yuanyuan Ge, Rong Wu, Jianguo Hu
Background and Aims Intestinal fibrotic stenosis is a major reason for surgery in Crohn's disease [CD], but the mechanism is unknown. Thus, we asked whether intestinal adipocytes contribute to intestinal fibrosis. Adipocytes were found to transdifferentiate into myofibroblasts and confirmed to be involved in mesenteric fibrosis in our recent study. Here, we investigated the role and possible mechanisms
-
Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-11 Shafquat Zaman, Ali Yasen Y Mohamedahmed, Widad Abdelrahman, Hashim E Abdalla, Ali Ahmed Wuheb, Mohamed Talaat Issa, Nameer Faiz, Nuha A Yassin
Background To evaluate outcomes of robotic versus conventional laparoscopic colorectal resections in patients with inflammatory bowel disease (IBD). Methods Comparative studies of robotic versus laparoscopic colorectal resections in patients with IBD were included. Primary outcome was total post-operative complication rate. Secondary outcomes included operative time, conversion to open surgery, anastomotic
-
Contrast enhanced endoscopic ultrasound detects early therapy response following anti-TNF-therapy in patients with ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-08 Mark Ellrichmann, Berenice Schulte, Claudio C Conrad, Stephan Schoch, Johannes Bethge, Marcus Seeger, Robert Huber, Madita Goeb, Alexander Arlt, Susanna Nikolaus, Christoph Röcken, Stefan Schreiber
Background and Aim Though colonoscopy plays a crucial role in assessing active ulcerative colitis (aUC), its scope is limited to the mucosal surface. Endoscopic ultrasound (EUS) coupled with contrast-enhancement (dCEUS) can precisely quantify bowel wall thickness and microvascular circulation, potentially enabling the quantitative evaluation of inflammation. We conducted a prospective, longitudinal
-
Disease acceptance, but not perceived control, is uniquely associated with inflammatory bowel disease-related disability J. Crohns Colitis (IF 8.0) Pub Date : 2024-03-06 Anouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, Bram Verstockt, João Sabino, Séverine Vermeire, Livia Guadagnoli, Ilse Van Diest, Marc Ferrante
Background and Aims Disability, an important aspect of disease burden in patients with inflammatory bowel disease (IBD), has been suggested as a valuable clinical endpoint. We aimed to investigate how disease acceptance and perceived control, two psychological predictors of subjective health, are associated with IBD-related disability. Methods In this cross-sectional study, adult IBD patients from
-
Unraveling the Oral-Gut axis: Interconnection between Periodontitis and IBD, Current Challenges, and Future Perspective J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-28 Himanshi Tanwar, Jeba Mercy Gnanasekaran, Devon Allison, Ling-shiang Chuang, Xuesong He, Mario Aimetti, Giacomo Baima, Massimo Costalonga, Raymond K Cross, Cynthia Sears, Saurabh Mehandru, Judy Cho, Jean-Frederic Colombel, Jean-Pierre Raufman, Vivek Thumbigere-Math
As the opposite ends of the orodigestive tract, the oral cavity and the intestine share anatomical, microbial, and immunological ties that have bidirectional health implications. A growing body of evidence suggests an interconnection between oral pathologies and Inflammatory Bowel Disease (IBD), implying a shift from the traditional concept of independent diseases to a complex, reciprocal cycle. This
-
The epidemiology of inflammatory bowel diseases during the COVID-19 pandemic: comparison of two nationwide cohorts J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-24 Ohad Atia, Nicklas Bryder, Adi Mendelovici, Natan Ledderman, Amir Ben-Tov, Mehdi Osooli, Anders Forss, Yiska Loewenberg Weisband, Eran Matz, Iris Dotan, Dan Turner, Ola Olén
Background We aimed to explore the epidemiology of inflammatory bowel diseases (IBD) in association with the COVID-19 pandemic in two countries with different lockdown policies. Methods We utilized nationwide IBD cohorts in Israel and Sweden to explore the incidence of IBD during the pandemic compared to three years prior (2017- 2019). We examined temporal trends through the presence of inflection
-
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-23 Joel R Rosh, Dan Turner, Jeffrey S Hyams, Marla Dubinsky, Anne M Griffiths, Stanley A Cohen, Kim Hung Lo, Lilianne Kim, Sheri Volger, Renping Zhang, Richard Strauss, Laurie S Conklin
Background and Aims Most pediatric IBD studies are performed after medications are approved in adults and the majority of participants in these studies are adolescents. We hypothesized that adolescent-onset IBD is not fundamentally different than adult-onset IBD. If this is correct, the value of delaying access to novel drugs in adolescents becomes questioned. Methods Data from 11 randomized, double-blind
-
Thiopurine metabolite shunting in late pregnancy increases the risk of intrahepatic cholestasis of pregnancy in women with inflammatory bowel disease, and can be managed with split-dosing J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-17 Ralley Prentice, Emma Flanagan, Emily Wright, Lani Prideaux, William Connell, Miles Sparrow, Peter De Cruz, Mark Lust, Winita Hardikar, Rimma Goldberg, Sara Vogrin, Kirsten Palmer, Alyson Ross, Megan Burns, Tessa Greeve, Sally Bell
Background and Aims The risk of intrahepatic cholestasis of pregnancy (ICP) is increased in thiopurine exposed pregnancies. Thiopurine ‘shunting’, with a 6-methylmecrcaptopurine (MMP) to 6-thioguanine (TGN) ratio of >11, progresses over pregnancy, and may promote ICP development. We aimed to explore the association between thiopurine exposure and ICP, including the hypothesized impact of thiopurine
-
Specific antibiotics increases the risk of flare-ups in patients with inflammatory bowel disease – results from a Danish nationwide population-based nested case-control study J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-17 Bobby Lo, Luc Biederman, Gerhard Rogler, Barbara Dora, Andrea Kreienbühl, Ida Vind, Flemming Bendtsen, Johan Burisch
Introduction IBD patients have a relapsing-remitting disease course, and amongst environmental factors that aggravate the disease course, common drugs aside from NSAIDs are not studied in detail. While the microbiome is considered to play a significant role on the disease course the impact of antibiotics is poorly understood. This study investigated the potential impact of different classes of antibiotics
-
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulizing Crohn’s Disease [DIVERGENCE 2]: a Phase 2, Randomized, Placebo-Controlled Trial J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-17 Walter Reinisch, Jean-Frederic Colombel, Geert R D’Haens, Jordi Rimola, Tomasz Masior, Matt McKevitt, Xuehan Ren, Adrian Serone, David A Schwartz, Krisztina B Gecse
Background and Aims There is an unmet need for the treatment of perianal fistulizing Crohn’s disease [PFCD]. This study evaluated the efficacy and safety of the Janus kinase 1 preferential inhibitor filgotinib, for the treatment of PFCD. Methods This phase 2, double-blind, multicentre trial enrolled adults with PFCD and prior treatment failure. Participants were randomized [2:2:1] to receive filgotinib
-
Peripheral joint and enthesis involvement in patients with newly diagnosed inflammatory bowel disease: symptoms, clinical and ultrasound findings – a population-based cohort study J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-16 Nora Vladimirova, Lene Terslev, Mohamed Attauabi, Gorm Madsen, Viktoria Fana, Charlotte Wiell, Uffe Møller Døhn, Flemming Bendtsen, Jakob Seidelin, Johan Burisch, Mikkel Østergaard
Objectives Musculoskeletal manifestations in patients with inflammatory bowel disease (IBD) are common and associated with poorer outcomes. Hence, early detection is important to optimally tailor treatment. We aimed to determine the prevalence and distribution of inflammatory lesions in peripheral joints and entheses in newly diagnosed IBD patients. Design Patients with newly diagnosed IBD from a prospective
-
The phospholipid flippase ATP8B1 is involved in the pathogenesis of Ulcerative Colitis via establishment of intestinal barrier function J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-15 Pim J Koelink, Valentina E Gómez-Mellado, Suzanne Duijst, Manon van Roest, Sander Meisner, Kam S Ho-Mok, Sabrina Frank, Babette S Appelman, Lysbeth ten Bloemendaal, Georg F Vogel, Stan F J van de Graaf, Piter J Bosma, Ronald P J Oude Elferink, Manon E Wildenberg, Coen C Paulusma
Objective Patients with mutations in ATP8B1 develop Progressive Familial Intrahepatic Cholestasis type 1 (PFIC1), a severe liver disease that requires life-saving liver transplantation. PFIC1 patients also present with gastrointestinal problems, including intestinal inflammation and diarrhea, which are aggravated after liver transplantation. Here we investigate the intestinal function of ATP8B1 in
-
Tobacco smoke exposure in early childhood and later risk of inflammatory bowel disease: A Scandinavian birth cohort study J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-08 Ida Sigvardsson, Johnny Ludvigsson, Björn Andersson, Ketil Størdal, Karl Mårild
Objectives To examine the association between early-life smoking exposure and later risk of inflammatory bowel disease (IBD) Methods We followed 115,663 participants from the Norwegian Mother, Father and Child (MoBa) and All Babies in Southeast Sweden (ABIS) cohorts from birth (1997-2009) through 2021. IBD was identified through national patient registers. Validated questionnaire data defined maternal
-
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-02-04 Subrata Ghosh, Brian G Feagan, Elyssa Ott, Christopher Gasink, Bridget Godwin, Colleen Marano, Ye Miao, Tony Ma, Edward V Loftus, William J Sandborn, Silvio Danese, Maria T Abreu, Bruce E Sands
Background and Aims Previously published long-term safety data reported a favorable ustekinumab safety treatment profile for treatment of inflammatory bowel disease (IBD). We present the final cumulative safety data from pooled ustekinumab IBD phase 2/3 clinical studies through 5 years in Crohn’s disease (CD) and 4 years in ulcerative colitis (UC). Methods In phase 3 studies, patients received a single
-
Intestinal epithelia and myeloid immune cells shape colitis severity and colorectal carcinogenesis via High-mobility group box protein 1 J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-29 Katharina Foelsch, Penelope Pelczar, Elisabeth Zierz, Stephanie Kondratowicz, Minyue Qi, Christian Müller, Malik Alawi, Sina Huebener, Till Clauditz, Nicola Gagliani, Samuel Huber, Peter Huebener
Background HMGB1 is a ubiquitous nucleoprotein with immune-regulatory properties following cellular secretion or release in sterile and infectious inflammation. Stool and serum HMGB1 levels correlate with colitis severity and colorectal cancer (CRC) progression, yet recent reports indicated HMGB1 to mainly operate as an intracellular determinant of enterocyte fate during colitis, and investigations
-
Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-25 James Kuo, Jasmina Uzunovic, Amanda Jacobson, Michelle Dourado, Sarah Gierke, Manohary Rajendram, Daniela Keilberg, Jordan Mar, Emily Stekol, Joanna Curry, Sofia Verstraete, Jessica Lund, Yuxin Liang, Fiona B Tamburini, Natalie S Omattage, Matthieu Masureel, Steven T Rutherford, David H Hackos, Man-Wah Tan, Allyson L Byrd, Mary E Keir, Elizabeth Skippington, Kelly M Storek
Background and Aims The goal was to identify microbial drivers of IBD, by investigating mucosal-associated bacteria and their detrimental products in IBD patients. Methods We directly cultured bacterial communities from mucosal biopsies from pediatric gastrointestinal patients and examined for pathogenicity-associated traits. Upon identifying C. perfringens as toxigenic bacteria present in mucosal
-
P518 Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A Jatkowska, B White, I Campbell, E Brownson, B Short, J Clowe, J P Seenan, D R Gaya, S Din, G T Ho, E Robertson, C Mowat, S Milling, J MacDonald, K Gerasimidis
Background Biologics, such as anti-TNFα agents, are commonly used in the management of Crohn’s disease (CD). A significant proportion of patients do not respond to treatment, necessitating the exploration of pre-treatment predictors of treatment response. Methods Anti-TNFα-naïve adults with active CD (Crohn’s Disease Activity Index; CDAI≥150) participating in an RCT (NCT04859088) were randomised to
-
P611 Relation between AntiTNF levels during the induction and clinical and radiological outcomes in perianal Crohn´s disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 C Amiama Roig, C Suarez Ferrer, E Martin Arranz, J L Rueda Garcia, M Sánchez Azofra, J Poza Cordón, I Gonzalez Diaz, C Amor Costa, M D Martín-Arranz
Background Perianal Crohn's disease(PCD) significantly impacts quality of life with poor long-term prognosis. Anti-tumor necrosis factor(anti-TNF) therapy improves fistula closure rates. However, achieving permanent closure remains challenging. Our aim is to evaluate the relation between antiTNF(infliximab (IFX) and adalimumab(ADA) serum concentrations at induction(w2 and 6), and clinical and radiological
-
P697 Short- and long-term outcomes following biologic use before non-conventional stricureplasty for Crohn’s Jejunoileitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 M Belkovsky, B Cohen, J Sommovilla, T Hull, S Holubar
Background Non-conventional strictureplasties, specifically the Finney and Michelassi technique, are bowel-preserving surgical techniques for diffuse jejunoileal Crohn’s Disease (CD). We investigated the association of biologic use during non-conventional strictureplasty for Crohn's jejunoileitis and its short- and long-term outcomes. Methods We conducted a retrospective review of all patients with
-
P525 Utilisation of endoscopic ultrasonography for submucosal cushion measurement to determine eligibility for endoscopic submucosal dissection in ulcerative colitis-associated dysplasia: A case series J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 K Kim, S W Hong, S W Hwang, S H Park, B D Ye, J S Byeon, S J Myung, S K Yang, D H Yang
Background Endoscopic submucosal dissection (ESD) has gained traction as an effective therapy for ulcerative colitis (UC)-associated dysplasia, yet identifying fitting ESD candidates is challenging by substantial submucosal (SM) fibrosis from chronic inflammation. We report our experience utilising endoscopic ultrasonography (EUS) to assess ESD eligibility by measuring SM cushion thickness. Methods
-
P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A Afzali, M Regueiro, A J Yarur, Y Zabana, S C Ng, S S Menon, A McDonnell, K Lazin, M Keating, A Bhattacharjee, D Branquinho, E Bananis, L Peyrin-Biroulet
Background Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the other S1P receptor modulator approved for UC, etrasimod and its metabolites do not have a molecular structure to inhibit monoamine oxidase (MAO).1 Coadministration of drugs that inhibit MAO with opioids
-
P016 Reduction of mucosal (active) eosinophils, B cells and T cells after vedolizumab therapy in patients with ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 I Jacobs, J Cremer, M Ferrante, J Sabino, S Vermeire, C Breynaert, T Vanuytsel, B Verstockt
Background Patients with ulcerative colitis (UC) are often treated with biological therapies or small molecules. Knowledge about the impact of these therapies on the intestinal and peripheral blood immune cell composition is scarce. Therefore, we investigated how advanced therapies modulate immune cell distribution in UC patients. Methods We included 30 UC patients (53% male, median age 42 years) who
-
P222 Inflammatory Bowel Disease and cardiac function: a systematic review of literature with meta-analysis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 C Soares, J Fiuza, C Rodrigues, J Gil, N Craveiro, P Ministro
Background Morphological and functional cardiac involvement is rarely seen in inflammatory bowel disease (IBD) patients but there is evidence that IBD patients have an increased risk of cardiovascular events despite the lower prevalence of traditional cardiovascular (CV) risk factors when compared to the general population. Our systematic review and meta-analysis examined the relationship between IBD
-
P424 Analysis of the intestinal microbiome using an Endoscopic Brush in Ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 B Lee, B Keum, S Kim, H Jeon, Y Jeen, C Hoonjai
Background The precise pathogenesis of the Ulcerative colitis is still yet unknown, but one of its cause is known to be microbial dysbiosis. The mucosa-associated microbiota are more deeply involved in the pathogenesis of UC. However, the optimal sampling of mucosa-associated microbiome has yet to be investigated. In this study, we investigated the mucosa-associated microbiome in patients with ulcerative
-
DOP63 Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 M Malham, S Jansson, H A S Ingels, M H Jørgensen, N Roed, A V Wewer, M P Fox
Background Patients with pediatric-onset immune-mediated inflammatory diseases (pIMID) show more aggressive phenotypes compared to patients diagnosed as adults. Despite this, data on mortality is extrapolated from patients diagnosed in adulthood, which might underestimate the actual risk. We aim to estimate the effect of pIMID compared to reference individuals from the general population on the long-term
-
DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 B Marius, N Rolhion, L Creusot, A Lefevre, I Alonso, L Brot, C Danne, A Bourrier, L Parrot, D Mélanie, N Benech, I Nion-Larmurier, P Mclellan, C Landman, L Beaugerie, P Seksik, P Emond, J Kirchgesner, H Sokol
Background Alterations in gut microbiota composition and functions are involved in the pathogenesis of Inflammatory Bowel Disease (IBD) and the role of specific bacterial taxa has been particularly pointed out. The role of microbiota-derived metabolites, including those produced from tryptophan, are major actors in host-microbiota interactions in health and in IBD. Large studies analyzing both gut
-
P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A Buisson, A Amiot, M Nachury, R Altwegg, M Serrero, T Guilmoteau, X Treton, L Caillo, L Vuitton, G Bouguen, B Pereira, M Fumery
Background STRIDE 2 recommendations define clinical remission as no rectal bleeding and normalization of stool frequency in patients with ulcerative colitis (UC), without including bowel urgency (BU) despite its negative impact on quality of life. In this large multicenter cohort, we aimed to assess whether the persistence of BU after induction therapy is independently associated with poor long-term
-
P264 The utility of ANCA in Ulcerative Colitis and Crohn’s Disease: A Retrospective Cohort Study in Taiwan J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 Y H Wu, C P Wang, P J Huang, H C Lai, K S Cheng, J W Chou
Background Inflammatory bowel disease (IBD) includes two chronic idiopathic inflammatory diseases: ulcerative colitis (UC) and Crohn disease (CD). The diagnosis of IBD depends on clinical, endoscopic, histological, radiological and biochemical criteria, which may be invasive, time consuming and usually not accepted by patients with IBD. Antineutrophil cytoplasmic antibodies (ANCAs) is believed to be
-
P028 A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 Y Yasutomi, A Chiba, K Haga, G Murayama, A Makiyama, T Kuga, A Nagahara, T Nagaishi, S Miyake
Background It is known that the mucosal-associated invariant T (MAIT) cells are the innate-like T cells that are restricted by the major histocompatibility complex-related molecule 1 (MR1), and that these cells express a semi-invariant T cell receptor. We have previously reported that the activation status of the circulating MAIT cells in patients with Ulcerative Colitis (UC) is associated with disease
-
P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Danese, J F Colombel, F Rieder, L Peyrin-Biroulet, B Siegmund, S Vermeire, M Dubinsky, S Schreiber, A Yarur, R Panaccione, B Feagan, R Mosig, F Cataldi, B Verstockt
Background Immunometabolism exerts a bimodal action at the interface of extracellular immune response and intracellular metabolism. It controls both intracellular processes and extracellular inflammatory responses by regulating both cellular energy supply & demands, factors that determine how a cell responds to the extracellular signals. Hence, immunometabolic pathways represent an attractive target
-
OP07 Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResource J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Balarajah, L Martinez-Gili, J Alexander, B Mullish, R Perry, J Li, J Marchesi, M Parkes, T Orchard, L Hicks, H Williams
Background The current evidence suggests ethnic distinctions in IBD phenotype, and differences in the provision of treatment have been reported. This multi-centre cohort study utilised the UK IBD BioResource dataset to evaluate phenotypic differences between South Asian (SA) and White (WH) IBD, and to explore if these were associated with differences in treatment. Methods Phenotypic and outcome data
-
P1101 Patient-reported physical activity of IBD patients is of concern when weighed with the international physical activity questionnaire regardless of disease activity and IBD phenotype: barriers and facilitators emerged from the extended "BE-FIT-IBD" cross-sectional study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A G Gravina, R Pellegrino, G Palladino, G Imperio, R D'Onofrio, G Arboretto, M Romeo, P Ciamarra, M Dallio, A Federico
Background As the World Health Organization recommends, regular physical activity (PA) determines quality of life. The qualitative/quantitative characteristics of ideal PA to be suggested for inflammatory bowel diseases (IBD) nor the relationship with disease activity are not yet well defined. This study aimed to weigh PA levels and barriers/facilitators to PA in a cross-sectional group of patients
-
P196 Pregnancy and perinatal outcomes of Inflammatory Bowel Disease mothers in Taiwan - a nationwide health and welfare databases analysis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 H Y Wu, C N Chen, M T Weng, C B Huang, P N Tsao, S C Wei
Background The incidence of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), has exhibited a consistent rise in recent years across Asia and Taiwan. Existing literature suggests that women with IBD may experience suboptimal perinatal outcomes. However, the specific relationship between IBD in pregnant Taiwanese women and the subsequent health outcomes of
-
P310 Intestinal ultrasound as a tool to assess treatment response in patients with Inflammatory Bowel Diseases J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 M Katsaros, A Katsoula, M Kalogirou, P Paschos, P Papagiannakis, T Tsionis, O Giouleme
Background The assessment of treatment response in patients with Inflammatory Bowel Disease (IBD) is often based on clinical indices [Harvey Bradshaw index (HBI), Partial Mayo score (PMS)] and biomarkers [C - reactive protein (CRP)]. Intestinal ultrasound (IUS) has been proposed as a modality capable of objectively evaluating therapeutic response. We investigated the utility of the IUS as a tool to
-
P886 Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 X Serra-Ruiz, E Céspedes Martínez, L Mayorga Ayala, C Herrera de-Guise, V Robles Alonso, Z Pérez Martínez, E Oller, N Borruel Sainz
Background It is unclear whether ustekinumab (UST) concentrations can predict the clinical course of inflammatory bowel disease (IBD) and guide treatment algorithms during the induction phase. The aim of our study was to assess the association between serum UST concentrations during the induction phase and clinical outcomes at week 24 and to determine the validity of a UST threshold for guiding intensification
-
P1123 Social isolation, loneliness, and incident inflammatory bowel disease: results from a large prospective cohorts and Mendelian randomization J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 J Zhao, M Zhang, J Ye, X Li
Background Background Social isolation and loneliness pose significant public health challenges globally. The objective of this study is to investigate the association between social isolation, loneliness, and the risk of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD). Methods Methods 275,157 UK adults from the UK Biobank (UKB) was analyzed. The exposures of interest
-
P949 Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study. A multicenter study from the young group of GETECCU J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 E Fuentes-Valenzuela, I Bastón-Rey, F J García-Alonso, E Leo Carnerero, I Garcia de la Filia, A Pedraza Pérez, R M Sáiz Chumillas, A Pascual Oliver, C Muñoz Villafranca, V Moreno, C Suárez Ferrer, G Molina Arriero, R Ferreiro-Iglesias, P Vega Villaamil, D Gardeazábal Mateos, J X Segarra-Ortega, A Garrido Marín, A I Doallo, A Elosua, H Alonso-Galán, E Brunet- Mas, N Jimenez García, F López Romero-Salazar
Background Few small studies have assessed the efficacy of topical therapy with tacrolimus in patients with ulcerative colitis (UC). The aim of our study was to evaluate its effectiveness and safety in a real-world setting. Methods A multicenter observational retrospective study at 25 Spanish GETECCU hospitals was performed. Adult patients with UC who received topical tacrolimus from January 2009 to
-
P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study) J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A Giordano, I Pérez Martínez, J P Gisbert, E Ricart, M A M Dolores, F Mesonero, D C P M Luisa, M Rivero, E Iglesias Flores, S Fernández-Prada, M Calafat, M Arroyo Villarino, M Á de Jorge Turrión, E Rodríguez-González, P Corsino Roche, D Carpio, E Brunet, F Rodriguez Moranta, L Arias García, I Pascual, F Bermejo, L Madero, M Esteve, C González Muñoza, P Martínez-Montiel, J M Huguet, J L Pérez Calle
Background Crohn's disease (CD) presents differences in genetics, inflammatory components, and microbiota depending on its location. Therapy efficacy may be linked to disease location, but existing research has yielded conflicting results. This study aims to investigate the impact of CD location on first-line biologic therapy requirement and persistence and the risk of intestinal resections. Methods
-
P696 Initiation of Vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A Prospective Study Including Rheumatological and Blinded Imaging Assessments J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Rohekar, T Boyd, R Lambert, M Beaton, N Chande, J Gregor, H Lennox, K McIntosh, T Ponich, A Rahman, T Sharma, M Sey, M Tauqir, V Jairath
Background Prior case series indicated a temporal relationship between use of vedolizumab and new-onset spondyloarthritis. Methods We aimed to evaluate the relationship between initiation of vedolizumab and development of new-onset spondyloarthritis in patients with inflammatory bowel disease, through serial clinical evaluation and magnetic resonance imaging. A single-centre prospective observational
-
P743 A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 A Croft, S Okano, G Hartel, A Lord, G Walker, G Radford-Smith
Background An episode of acute ulcerative colitis (UC) represents an important watershed moment in a patient’s disease course. Foreknowledge of a patient's likely response to intravenous corticosteroid therapy has significant clinical utility. Using a large prospectively collected acute UC patient database and machine learning-based techniques we aimed to derive and validate a personalised algorithm
-
P958 Comparison of Paediatric Patients and Young Adults with Moderately to Severely Active Crohn’s Disease Treated with Ustekinumab in the REALITI Real-World Evidence Effectiveness Study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Steiner, S Shehzad, J Adler, R B Colletti, R Strauss, J Heile, O Adedokun, A Sheahan, R Zhang, K H Lo, L Kim, Y Xiao, S Volger
Background Few approved treatment options exist for paediatric patients (pts) with Crohn’s disease (CD). Paediatric inflammatory bowel disease (IBD) medication approvals are delayed nearly 7 years after adult approvals,1 resulting in off-label use and potential for incorrect dosing. The REALITI Study evaluated the effectiveness and safety of ustekinumab (UST) in routine clinical care in paediatric
-
P335 Development and validation of a Belgian set of quality indicators for inflammatory bowel diseases J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 L Fierens, C Liefferinckx, J Sabino, E de Dycker, V Wambacq, K Vanhaecht, F Rademakers, P Bossuyt, F Baert, D Baert, M Ferrante
Background Quality indicators are standardized, evidence-based measures of health care quality, categorised as structure (to assess the care setting), process (to assess high-quality care actions by healthcare professionals) or outcome indicators (results of actions undertaken by healthcare professionals). Several quality indicator sets have been developed to standardise, measure and optimise IBD care
-
P698 Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentre Real-World Observational Study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 R Parra, J M F Chebli, M Freitas Cardoso de Azevedo, L A Chebli, G P Zabot, O S Cassol, R D S B Fróes, G O Santana, M Lubini, D O Magro, M Imbrizi, A C S Moraes, F V Teixeira, A J T Alves Jr, N L T Gasparetti Junior, S D C Ferreira, N S F Queiroz, P G Kotze, O Féres
Background Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking in Latin America. In this study, we aimed to describe the effectiveness and safety of UST in a real-world multicentre cohort of Brazilian patients with UC. Methods We conducted a multicentre retrospective observational cohort study, including patients with moderate to severe UC (Total
-
P465 Upadacitinib is effective and safe for the treatment of ulcerative colitis and Crohn’s disease: 1-year prospective real-world experience J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 N Krugliak Cleveland, N K Choi, J A Klein, E N Fear, Z D Fine, N M Garcia, E A Picker, S R Friedberg, R D Cohen, S R Dalal, J Pekow, D Choi, D T Rubin
Background Upadacitinib (UPA) is a novel selective Janus kinase 1 inhibitor that has shown efficacy and received approval for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD). We previously reported a large real-world experience of UPA induction in UC and CD (Friedberg, CGH. 2023). Here we report our 1-year real-world experience. Methods This is a prospectively collected
-
P1229 The Role and Niche-Specific Adaptation of Malassezia in patients with Ulcerative colitis J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Shin Shin, Y J Cho, J Yang, H K Kim, P Rintarhat, M Park, K Lagree, D M Underhill, C S Yang, J M Moon, J Seo, K Kim, W H Jung, C H Choi
Background Accumulating evidence has underscored the role of gut fungal microbiota (mycobiota) in the development of inflammatory bowel disease. We aimed to isolate a Malassezia strain directly from the human intestine mucosal surface from the patients with ulcerative colitis (UC) and investigated its genome and virulence in comparison with the same fungal species isolated from the human skin. Methods
-
N03 Flexibility & Accessibility, e-Literacy, Resourcing and The Human Factor: Early Lessons from EIBD, a UK Qualitative Interview Study J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 P Avery, K Kemp, L Dibley, S Green
Background Since the COVID-19 pandemic, the use of health tools (video/phone consultations, patient portals, and digital applications) has increased in the clinical management of patients with Inflammatory Bowel Disease (PIBD). We aimed to evidence the acceptability of eHealth tools by investigating the shared experience of PIBD and healthcare professionals (HCPs) in using eHealth to carry out follow-up
-
P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 B Gros, N Manceñido Marcos, J Guardiola, I Alonso Abreu, I Rodríguez Lago, R Alvarado, Á Ponferrada, J Orobitg Bernades, F Argüelles-Arias, F Mesonero, I Guerra, F Cañete, L Madero, P Borràs, G E Rodríguez, M Iborra, J Castro, A Caballero Mateos, M Barreiro-de Acosta, J M Huguet Malavés, E Brunet-Mas, F López Romero-Salazar, B Caballol, Y Zabana, C Suria Bolufer, P Soto, B Castro, S Marín, S Porto-Silva
Background Despite the established use of intravenous (IV) vedolizumab for treating inflammatory bowel disease (IBD), there's growing interest in exploring the advantages of the novel subcutaneous (SC) administration route. However, comprehensive real-world evidence regarding the extended safety and effectiveness of this approach remains scarce. The aim of the study was to evaluate the effectiveness
-
P479 The prevalence and risk factors of hematologic malignancy in patients with intestinal Behçet’s disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Choi, J H Ji, S J Park, J J Park, J H Cheon, T I Kim, J Park
Background The association of intestinal Behçet’s disease (BD) with the risk of hematologic malignancy is still unclear. We aimed to assess the prevalence and determine risk factors of hematologic malignancy in intestinal BD. Methods Using a cohort of patients with intestinal BD between 1997 and 2021, the prevalence and risk factors of hematologic malignancy were analysed by logistic regression analysis
-
P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 B Verstockt, S Vermeire, L Peyrin-Biroulet, A Yarur, R Panaccione, R Mosig, F Cataldi, S Danese
Background NLRX1 activation reduces inflammation by decreasing oxidative stress and altering cellular metabolism within multiple cell types implicated in ulcerative colitis (UC). Colitis animal models demonstrated reduced disease severity and a phase 1b clinical trial showed signs of rapid symptom and endoscopic improvement in patients with active UC.1, 2 Abdominal pain driven by visceral hypersensitivity
-
P915 Multi-Omics Biomarkers for the Prediction of Response to Biologics in Patients with Inflammatory Bowel Disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 L Chen, C Zhang, R Niu, R Mao, Y Qiu, R Feng
Background The treatment concept for inflammatory bowel disease (IBD) has been transformed with biologics now recommended as the first-line therapy for moderate-to-severe patients. However, the significant heterogeneity among IBD patients has limited the efficacy of selected biologics based on traditional clinical factors. Therefore, it is imperative to molecularly stratify patients to match them with
-
P1200 Study of correlation between polymorphisms of vitamin D metabolism genes and perianal disease in Crohn's disease J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 D G Ribaldone, C Cafasso, M Antonucci, A Palermiti, G P Caviglia, M Vernero, A D'Avolio, J Cusato
Background Vitamin D (VD) is a fat-soluble vitamin essential for calcium homeostasis and that acts at the extraskeletal level. UVB skin exposure allows the synthesis of provitamin D. This undergoes a first hydroxylation in the leaver by the CYP2R1 enzyme and a second hydroxylation in the kidney by the CYP27B1 enzyme: active VD is obtained. VD is transported into the circulation by VDBP and exerts its
-
P661 Ustekinumab in Crohn’s disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safety J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 L J Barkai, L Gonczi, K Farkas, B Farkas, T Molnar, T Szamosi, E Schafer, P Golovics, M Juhasz, A Patai, A Vincze, P Sarlos, A Farkas, Z Dubravcsik, T G Toth, P Miheller, P L Lakatos, A Ilias
Background While randomized controlled trials have shown ustekinumab (UST) as an effective therapeutic option for Crohn’s disease (CD), there is a lack of long-term observational data in real-world CD patient settings. This prospective study seeks to evaluate the clinical effectiveness, sustainability, and safety of UST in a nationwide multicentre cohort of CD patients over three years. The aim is
-
P905 Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib - First results from the IBD-DACH study EUROPE J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 S Zeissig, R Schmelz, U Helwig, A R Moschen, T Greuter, I Fischer, L Hammer, S Rath, T Kucharzik, C Maaser
Background Upadacitinib (UPA) is an oral, reversible and selective Januskinase-inhibitor (JAKi) that was approved for the treatment of several immune-mediated inflammatory diseases, including moderate to severe ulcerative colitis (UC) (1). While the efficacy of UPA has been demonstrated in clinical trials in UC, real-word (RW) evidence on the effectiveness and safety of UPA in UC remains scarce (2)
-
P701 Evaluation of the effectiveness of vedolizumab in patients with Crohn's disease: a multicenter real-life study from Argentina J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 D C Balderramo, J Etchevers, C Fuxman, P Lubrano, M Bellicoso, G Correa, J Trakal, M R Defago, J Montero, M Toro, A Novillo, M Bonardo, N Arancibia, S Motañez, S Quines, S Huernos, A Gil, R Gonzalez, S Goncalves
Background Vedolizumab (VDZ) is a gut-selective integrin inhibitor used to treat Crohn's disease (CD). Most of the information regarding real-life data on response to VDZ has been published from North America and Europe cohorts and there is scarce information from Latin America related to effectiveness of VDZ in patients with CD. The aims of this study were: i) to describe the clinical characteristics
-
P169 Circulating eNAMPT predicts anti-TNF response in IBD patients: possible place in therapy of anti-eNAMPT antibody J. Crohns Colitis (IF 8.0) Pub Date : 2024-01-24 C Travelli, G Cascetta, G colombo, A Alessi, E Caputo, M V Lenti, A Pasini, C Porta, D Ribaldone, L Pastorelli, A Di Sabatino, A Genazzani, G P Caviglia, G Stocco
Background extracellular Nicotinamide phosphoribosyltrasferase (eNAMPT) is a cytokine with paracrine and autocrine effects on different cell types. Importantly, eNAMPT levels are increased in patients suffering of Inflammatory Bowel Diseases (IBD). Biologic drugs have been found effective in many IBD patients; however, a large proportion of patients with severe disease fail to achieve remission due